Evidence map›Paper›PMID 30850442›Full record

ArticleNeurology2019

Risk factors for suicidality in Huntington disease: An analysis of the 2CARE clinical trial.

Andrew McGarry, Michael P McDermott, Karl Kieburtz, Wai Lun Alan Fung, Elizabeth McCusker, Jing Peng, Elisabeth A de Blieck, Merit Cudkowicz, Huntington Study Group 2CARE Investigators and Coordinators

Registry-linked trialOpen access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00608881 (Coenzyme Q10 in Huntington's Disease), which is not on this map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.0field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00608881 phase3terminatednot on this map

Coenzyme Q10 in Huntington's Disease (HD)

TypeinterventionalSponsorMassachusetts General HospitalRan2008 to 2015Enrolled609ConditionsHuntington's DiseaseArmscoenzyme Q10, placebo
3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 24 citations in OpenAlex.

  1. Association between irritability and suicidal ideation in three clinical trials of adults with major depressive disorder.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2020
    Trial
  2. Trial
  3. The pathobiology of depression in Huntington's disease: an unresolved puzzle.Journal of neural transmission (Vienna, Austria : 1996) · 2024
    Review
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Andrew McGarryFrom Cooper University Healthcare at Rowan University (A.M.), Camden, NJ; University of Rochester (M.P.M., K.K., E.A.d.B.), NY; North York General Hospital (W.L.A.F.), University of Toronto, Canada; Westmead Hospital (E.M.), Australia; The Ohio State University (J.P.), Columbus; and Harvard Medical School (M.C.), Boston, MA. mcgarry-andrew@cooperhealth.edu.
Michael P McDermottFrom Cooper University Healthcare at Rowan University (A.M.), Camden, NJ; University of Rochester (M.P.M., K.K., E.A.d.B.), NY; North York General Hospital (W.L.A.F.), University of Toronto, Canada; Westmead Hospital (E.M.), Australia; The Ohio State University (J.P.), Columbus; and Harvard Medical School (M.C.), Boston, MA.
Karl KieburtzFrom Cooper University Healthcare at Rowan University (A.M.), Camden, NJ; University of Rochester (M.P.M., K.K., E.A.d.B.), NY; North York General Hospital (W.L.A.F.), University of Toronto, Canada; Westmead Hospital (E.M.), Australia; The Ohio State University (J.P.), Columbus; and Harvard Medical School (M.C.), Boston, MA.
Wai Lun Alan FungFrom Cooper University Healthcare at Rowan University (A.M.), Camden, NJ; University of Rochester (M.P.M., K.K., E.A.d.B.), NY; North York General Hospital (W.L.A.F.), University of Toronto, Canada; Westmead Hospital (E.M.), Australia; The Ohio State University (J.P.), Columbus; and Harvard Medical School (M.C.), Boston, MA.
Elizabeth McCuskerFrom Cooper University Healthcare at Rowan University (A.M.), Camden, NJ; University of Rochester (M.P.M., K.K., E.A.d.B.), NY; North York General Hospital (W.L.A.F.), University of Toronto, Canada; Westmead Hospital (E.M.), Australia; The Ohio State University (J.P.), Columbus; and Harvard Medical School (M.C.), Boston, MA.
Jing PengFrom Cooper University Healthcare at Rowan University (A.M.), Camden, NJ; University of Rochester (M.P.M., K.K., E.A.d.B.), NY; North York General Hospital (W.L.A.F.), University of Toronto, Canada; Westmead Hospital (E.M.), Australia; The Ohio State University (J.P.), Columbus; and Harvard Medical School (M.C.), Boston, MA.
Elisabeth A de BlieckFrom Cooper University Healthcare at Rowan University (A.M.), Camden, NJ; University of Rochester (M.P.M., K.K., E.A.d.B.), NY; North York General Hospital (W.L.A.F.), University of Toronto, Canada; Westmead Hospital (E.M.), Australia; The Ohio State University (J.P.), Columbus; and Harvard Medical School (M.C.), Boston, MA.
Merit CudkowiczFrom Cooper University Healthcare at Rowan University (A.M.), Camden, NJ; University of Rochester (M.P.M., K.K., E.A.d.B.), NY; North York General Hospital (W.L.A.F.), University of Toronto, Canada; Westmead Hospital (E.M.), Australia; The Ohio State University (J.P.), Columbus; and Harvard Medical School (M.C.), Boston, MA.
Huntington Study Group 2CARE Investigators and Coordinators
University of Rochester · USRowan University · USThe Ohio State University · USWestmead Hospital · AU

Funding

Coordination and Statistics for CoQ10 in HD [2CARE]R01NS052619 · NINDS · UNIVERSITY OF ROCHESTER · PI MCDERMOTT, MICHAEL P · 2005 to 2014
$13.5M
Coenzyme Q10 in Huntingtons DiseaseU01NS052592 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI CUDKOWICZ, MERIT E · 2008 to 2013
$7.3M
NINDS NIH HHS R01 NS052619NINDS NIH HHS U01 NS052592
6 · The paper itself

Abstract

objectiveMost suicidality literature in Huntington disease (HD) is based on natural history studies or retrospective reviews, but reports on risk factors from clinical trials are limited.

methodsWe analyzed 609 participants from 2CARE, a randomized, double-blind, placebo-controlled clinical trial with up to 5 years of follow-up, for risk factors related to suicidality. The primary outcome variable was the time from randomization until the first occurrence of either suicidal ideation or attempt. We also considered time from randomization until the first suicide attempt as a secondary outcome variable.

resultsDepression, anxiety, bipolar disorder, antidepressant or anxiolytic use, and prior suicide attempt at baseline were associated with time to ideation or attempt. Baseline employment status, marital status, CAG repeat length, tetrabenazine use, and treatment assignment (coenzyme Q

conclusionThese data suggest psychiatric comorbidities in HD are predictive of suicidal behavior while participating in clinical trials, reinforcing the importance of clinical surveillance and treatment towards lessening risk during participation and perhaps beyond. Designing a composite algorithm for early prediction of suicide attempts in HD may be of value, particularly given anticipated trials aimed at disease modification are likely to be long-term. CLINICALTRIALSGOV IDENTIFIER: NCT00608881.

Indexed as

Suicidal IdeationAdrenergic Uptake InhibitorsAdultAnti-Anxiety AgentsAntidepressive AgentsAnxiety DisordersBipolar DisorderDepressive DisorderEmploymentFemaleHumansHuntingtin ProteinHuntington DiseaseMaleMarital StatusMiddle AgedAdrenergic Uptake InhibitorsAnti-Anxiety AgentsAntidepressive Agentscoenzyme Q10HTT protein, humanHuntingtin ProteinTetrabenazineUbiquinoneVitamins

Identifiers

PMID30850442
PMCPMC6448454
OpenAlexW2922159033

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.